Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bois-Guillaume – page 41

671 clinical trials in Bois-Guillaume, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bois-Guillaume at a glance
671
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

671 trials in Bois-Guillaume

Open in trial search

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Idiopathic pulmonary fibrosis

Not recruiting

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Nephrotic syndrome

Not recruiting

Study of Rituximab, Prednisolone and Betamethasone in Adult Patients with First Episode of Minimal Change Nephrotic Syndrome to Prevent Disease Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Squamous cell carcinoma of head and neck

Not recruiting

Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Chronic kidney disease

Not recruiting

Study on the Effects of Dapagliflozin on Blood Vessel Health in Patients with Chronic Kidney Disease

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Centre Hospitalier Universitaire Rouen

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Prostate cancer

Not recruiting

Study on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate
  • Sponsor:Unicancer

Cholangitis sclerosing

Not recruiting

Study on Bezafibrate for Patients with Primary Sclerosing Cholangitis and Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary hypertension

Not recruiting

Study on Sotatercept for Treating Pulmonary Hypertension in Adults with Heart Failure

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effects of Methylprednisolone and Placebo on Ventilator Support Duration in Severe COPD Patients in Intensive Care

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier De Versailles

Septic shock

Not recruiting

Study on Nicotinamide for Preventing Kidney Problems in Septic Shock Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Human herpesvirus 6 encephalitis

Not recruiting

Study on Dexamethasone for Patients with Herpes Simplex Virus Encephalitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Bois-Guillaume

What the registry says about research in the country

01 Kidney Disease & Transplantation

Innovative research focusing on chronic kidney disease treatments and transplant outcomes, including studies of novel medications like baxdrostat and tegoprubart for improving patient care.

  • Kidney Transplant Rejection Prevention
  • CKD Management
  • Hypertension Control

Multiple trials evaluating new therapeutic approaches for transplant recipients and CKD patients.

02 Blood Disorders

Clinical investigations into treatments for various blood-related conditions, with emphasis on immune thrombocytopenia and thrombotic disorders.

  • Thrombotic Thrombocytopenic Purpura
  • Hemolytic Uremic Syndrome
  • Immunological Therapies

Advanced studies combining established and experimental treatments for better patient outcomes.

03 Infectious Disease Management

Research examining treatment strategies for viral infections and optimization of antibiotic therapy, particularly in elderly populations.

  • Cytomegalovirus Treatment
  • Antibiotic Management
  • Viral Pneumonia

Studies focused on improving treatment protocols and reducing antibiotic overuse.

04 Autoimmune Conditions

Investigation of novel therapies for vasculitis and related autoimmune disorders, including targeted biological treatments.

  • Takayasu Arteritis
  • ANCA-Associated Vasculitis
  • Goodpasture Disease

Evaluating new treatment combinations to improve disease management and patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.